2012logocontact

Deceptive Imprinting

dreamstime_12929493 dreamstime_3181230

 

Antigenic variation or “Deceptive Imprinting” is a common strategy by which many disease pathogens and cancer cells evade conventional vaccine strategies as well as host immune responses. The immune system has evolved to detect a register of molecular shapes that stimulate both cellular (helper and cytotoxic T cells) and humoral (B cells and antibodies) immune effector activities to neutralize the more common shapes shared by microbial and cellular invaders, which might disrupt the hosts’ physiology. Vaccine resistant pathogens have developed the ability to subvert these effector responses by displaying and presenting chemical shapes and sequences that have higher antigenic indexes than surrounding molecular structures to “decoy” the immune system. As a pathogen invades a host, the immune system preferentially makes a response to these decoy epitopes ignoring the rest of the pathogen’s structure.

The evolutionary success of pathogens employing immune decoying is the presentation of highly immunogenic epitopes, which can also undergo antigenic variation. This decoying effect is termed “Deceptive Imprinting” after the classic example of goslings imprinting on Konrad Lorenz. Such epitopes are often adjacent to those that are more conserved and serve more important structural and functional activities of the pathogen such as adhesion, binding, colonization, and/or virulence factors. This strategy keeps the immune system effectively misdirected from critical functional domains by establishing an antigenic hierarchy between genetically unstable decoy epitopes and other conserved surface structures of the pathogen. This phenomenon also appears to greatly reduce the polyclonal multi-epitope immune response to the pathogen effectively reducing the immune response to a more oligoclonal, single-epitope restricted fashion. Such a restricted response favors the emergence of immune escape mutants and is analogous to single antibiotic or anti-viral chemotherapy that often leads to drug resistant pathogens.

Search Site

Virus Developments

BMI is developing an AIDS vaccine and applying its Immune Dampening and Refocusing Technology to the outer HIV envelope glycoprotein gp120/gp41, which is the main mediator of viral fusion and entry with host receptors CD4 and chemokine receptors CCR5 and/or CXCR4.

The Latest Technology

Biological Mimetics, Inc. (“BMI”) was formed to commercialize innovative pharmaceutical products that will improve the quality of life and overall state of public health by combating resistant and emerging diseases in human and veterinary medicine. Our mission philosophy is to remain a creative and innovative biotechnology firm dedicated to improving the quality of life and overall state of public health through the application of novel technologies for the development and commercialization of human and veterinary biologics to address a long list of hitherto intractable disease targets involving viruses, bacteria, parasites, and cancer.

Research & Development

dreamstime_13272506Biological Mimetics, Inc. research and development includes veterinary applications such as:
Foot and Mouth Disease Virus , Infectious Pancreatic Necrosis Virus,
and
Porcine Reproductive and Respiratory Syndrome Virus.

Company News

blk triangleJune 2011: BMI announces collaborative research agreement with Crucell-BV for development of a universal influenza vaccine
blk triangleNov. 2010: BMI announces collaborative research agreement with GSK-Biologicals for development of an immune refocused vaccine for respiratory infection
blk triangleSept 2010: BMI is awarded a Qualifying Therapeutic Discovery Project Award
blk triangleJune 2010: BMI is awarded a Small Business Innovative Research Grant from the NIH for vaccine development
blk triangleNov. 2009: BMI is a prime contractor in the Fundamentals of Biology Program of DARPA/DSO for the study of modularity in biological systems
blk triangleMay 2008: BMI is awarded a subcontract for HIV vaccine development through the Henry M Jackson Institute for the Advancement of Military Medicine.
blk triangleJuly 2007: BMI is awarded a subcontract from DARPA through Rice University to study the evolution of pathogens
blk triangleJune 2007: BMI is awarded a subcontract from DARPA through VaxDesign (Orlando, Florida) to study immunogenicity of influenza